vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and SEALED AIR CORP (SEE). Click either name above to swap in a different company.
SEALED AIR CORP is the larger business by last-quarter revenue ($1.4B vs $1.1B, roughly 1.2× Elanco Animal Health Inc). SEALED AIR CORP runs the higher net margin — 3.1% vs -24.1%, a 27.3% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs 2.6%). SEALED AIR CORP produced more free cash flow last quarter ($257.7M vs $46.0M). Over the past eight quarters, SEALED AIR CORP's revenue compounded faster (2.7% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Sealed Air Corporation is a global provider of innovative packaging and protective solutions. Its core offerings include cushioning materials, food safety and preservation packaging, and sustainable waste-reducing packaging systems, serving retail, e-commerce, food and beverage, and industrial manufacturing markets worldwide.
ELAN vs SEE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.4B |
| Net Profit | $-276.0M | $43.8M |
| Gross Margin | 51.5% | 28.6% |
| Operating Margin | -22.6% | 11.4% |
| Net Margin | -24.1% | 3.1% |
| Revenue YoY | 12.2% | 2.6% |
| Net Profit YoY | -3350.0% | 700.0% |
| EPS (diluted) | $-0.55 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.0B | $1.4B | ||
| Q3 24 | $1.0B | $1.3B | ||
| Q2 24 | $1.2B | $1.3B | ||
| Q1 24 | $1.2B | $1.3B |
| Q4 25 | $-276.0M | $43.8M | ||
| Q3 25 | $-34.0M | $255.1M | ||
| Q2 25 | $11.0M | $93.1M | ||
| Q1 25 | $67.0M | $113.5M | ||
| Q4 24 | $-8.0M | $-7.3M | ||
| Q3 24 | $364.0M | $91.7M | ||
| Q2 24 | $-50.0M | $98.3M | ||
| Q1 24 | $32.0M | $82.0M |
| Q4 25 | 51.5% | 28.6% | ||
| Q3 25 | 53.4% | 29.8% | ||
| Q2 25 | 57.5% | 30.7% | ||
| Q1 25 | 57.3% | 30.9% | ||
| Q4 24 | 50.9% | 30.0% | ||
| Q3 24 | 52.2% | 30.1% | ||
| Q2 24 | 58.2% | 31.2% | ||
| Q1 24 | 57.3% | 30.3% |
| Q4 25 | -22.6% | 11.4% | ||
| Q3 25 | -4.4% | 13.8% | ||
| Q2 25 | 2.0% | 15.0% | ||
| Q1 25 | 5.0% | 14.5% | ||
| Q4 24 | -5.0% | 11.7% | ||
| Q3 24 | 54.3% | 13.9% | ||
| Q2 24 | -2.7% | 15.4% | ||
| Q1 24 | 1.0% | 14.0% |
| Q4 25 | -24.1% | 3.1% | ||
| Q3 25 | -3.0% | 19.0% | ||
| Q2 25 | 0.9% | 7.0% | ||
| Q1 25 | 5.6% | 9.0% | ||
| Q4 24 | -0.8% | -0.5% | ||
| Q3 24 | 35.3% | 6.9% | ||
| Q2 24 | -4.2% | 7.4% | ||
| Q1 24 | 2.7% | 6.2% |
| Q4 25 | $-0.55 | $0.30 | ||
| Q3 25 | $-0.07 | $1.73 | ||
| Q2 25 | $0.02 | $0.63 | ||
| Q1 25 | $0.13 | $0.77 | ||
| Q4 24 | $-0.01 | $-0.05 | ||
| Q3 24 | $0.73 | $0.63 | ||
| Q2 24 | $-0.10 | $0.67 | ||
| Q1 24 | $0.06 | $0.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $344.0M |
| Total DebtLower is stronger | $3.9B | $3.3B |
| Stockholders' EquityBook value | $6.5B | $1.2B |
| Total Assets | $13.4B | $7.0B |
| Debt / EquityLower = less leverage | 0.60× | 2.65× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $344.0M | ||
| Q3 25 | $505.0M | $282.5M | ||
| Q2 25 | $539.0M | $354.4M | ||
| Q1 25 | $487.0M | $335.2M | ||
| Q4 24 | $468.0M | $371.8M | ||
| Q3 24 | $490.0M | $386.0M | ||
| Q2 24 | $416.0M | $388.6M | ||
| Q1 24 | $345.0M | $352.8M |
| Q4 25 | $3.9B | $3.3B | ||
| Q3 25 | $4.0B | $4.0B | ||
| Q2 25 | $4.1B | $4.0B | ||
| Q1 25 | $4.4B | $4.2B | ||
| Q4 24 | $4.3B | $4.2B | ||
| Q3 24 | $4.4B | $4.3B | ||
| Q2 24 | $5.7B | $4.4B | ||
| Q1 24 | $5.8B | $4.5B |
| Q4 25 | $6.5B | $1.2B | ||
| Q3 25 | $6.7B | $1.2B | ||
| Q2 25 | $6.8B | $953.1M | ||
| Q1 25 | $6.4B | $797.9M | ||
| Q4 24 | $6.1B | $624.5M | ||
| Q3 24 | $6.5B | $771.2M | ||
| Q2 24 | $5.9B | $650.1M | ||
| Q1 24 | $6.1B | $598.3M |
| Q4 25 | $13.4B | $7.0B | ||
| Q3 25 | $13.6B | $7.1B | ||
| Q2 25 | $13.7B | $7.2B | ||
| Q1 25 | $12.9B | $7.0B | ||
| Q4 24 | $12.6B | $7.0B | ||
| Q3 24 | $13.3B | $7.3B | ||
| Q2 24 | $13.8B | $7.3B | ||
| Q1 24 | $14.0B | $7.2B |
| Q4 25 | 0.60× | 2.65× | ||
| Q3 25 | 0.59× | 3.34× | ||
| Q2 25 | 0.61× | 4.18× | ||
| Q1 25 | 0.69× | 5.26× | ||
| Q4 24 | 0.70× | 6.72× | ||
| Q3 24 | 0.67× | 5.62× | ||
| Q2 24 | 0.96× | 6.81× | ||
| Q1 24 | 0.95× | 7.49× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $293.6M |
| Free Cash FlowOCF − Capex | $46.0M | $257.7M |
| FCF MarginFCF / Revenue | 4.0% | 18.5% |
| Capex IntensityCapex / Revenue | 5.4% | 2.6% |
| Cash ConversionOCF / Net Profit | — | 6.70× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $458.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $293.6M | ||
| Q3 25 | $219.0M | $165.9M | ||
| Q2 25 | $237.0M | $136.6M | ||
| Q1 25 | $-4.0M | $31.9M | ||
| Q4 24 | $177.0M | $244.2M | ||
| Q3 24 | $162.0M | $170.5M | ||
| Q2 24 | $200.0M | $188.2M | ||
| Q1 24 | $2.0M | $125.1M |
| Q4 25 | $46.0M | $257.7M | ||
| Q3 25 | $127.0M | $119.6M | ||
| Q2 25 | $180.0M | $93.2M | ||
| Q1 25 | $-69.0M | $-12.0M | ||
| Q4 24 | $130.0M | $185.1M | ||
| Q3 24 | $120.0M | $115.2M | ||
| Q2 24 | $166.0M | $129.5M | ||
| Q1 24 | $-22.0M | $78.0M |
| Q4 25 | 4.0% | 18.5% | ||
| Q3 25 | 11.2% | 8.9% | ||
| Q2 25 | 14.5% | 7.0% | ||
| Q1 25 | -5.8% | -0.9% | ||
| Q4 24 | 12.7% | 13.6% | ||
| Q3 24 | 11.7% | 8.6% | ||
| Q2 24 | 14.0% | 9.7% | ||
| Q1 24 | -1.8% | 5.9% |
| Q4 25 | 5.4% | 2.6% | ||
| Q3 25 | 8.1% | 3.4% | ||
| Q2 25 | 4.6% | 3.3% | ||
| Q1 25 | 5.4% | 3.5% | ||
| Q4 24 | 4.6% | 4.4% | ||
| Q3 24 | 4.1% | 4.1% | ||
| Q2 24 | 2.9% | 4.4% | ||
| Q1 24 | 2.0% | 3.6% |
| Q4 25 | — | 6.70× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | 21.55× | 1.47× | ||
| Q1 25 | -0.06× | 0.28× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.45× | 1.86× | ||
| Q2 24 | — | 1.91× | ||
| Q1 24 | 0.06× | 1.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
SEE
| Protective Segment | $1.1B | 78% |
| Other | $292.0M | 21% |
| Pension Plans Defined Benefit | $7.9M | 1% |
